---
canonical_name: Angelica sinensis
alternate_names: Dong Quai, Dang Gui, Danggui, Radix Angelicae Sinensis, Chinese Angelica, Female Ginseng
canonical_topic: Angelica sinensis for Health & Longevity
short_topic_lc: angelica_sinensis
creation_date: 2026-0825-0535
creator_ai_fullname: Opus 5
ep_keywords: Traditional Chinese Medicine, TCM, Chinese Herbal Medicine, Blood Tonic Herbs
---

# Angelica sinensis for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5

**Also known as:** Dong Quai, Dang Gui, Danggui, Radix Angelicae Sinensis, Chinese Angelica, Female Ginseng
  
  
## Motivation

<!-- Author's note: This motivation section was written last, after every other section of this review was complete, so that it reflects the full scope of the evidence rather than a preliminary impression of it. -->

*Angelica sinensis* — sold in the West as dong quai — is the dried root of a plant in the celery family that has been a fixture of Chinese herbal practice for roughly two thousand years. It is classified there as a "blood tonic," and modern chemistry traces much of its activity to a small group of aromatic oils and plant acids that relax blood vessels and dampen inflammation.

The root reached Western shelves in the twentieth century mainly as a women's remedy for menstrual pain and menopausal flushing, and it is now among the most widely traded Chinese herbs in the world. It is rarely taken alone in its country of origin, where practice almost always pairs it with other herbs — a habit that makes judging the root on its own unusually difficult.

This review examines what controlled human research shows about *Angelica sinensis*: where the root and the formulas built around it shift measurable outcomes, where careful trials have found nothing at all, and where the main safety questions sit, including its behaviour alongside blood-thinning drugs and in hormone-sensitive tissue.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**
  
  
## Recommended Reading

High-level sources that discuss *Angelica sinensis* by name in substantial depth, spanning its chemistry, its pharmacology, and the two best-conducted controlled human trials of the root itself.

<!-- Author's note: A real-time search was performed for high-level, directly relevant content on Angelica sinensis / dong quai. Each of the six priority platforms was searched by name plus intervention through general web search, and lifeextension.com was searched on-site. Only Life Extension carries directly relevant content; the resulting list is supplemented with qualifying narrative reviews and primary randomized trials. -->

* [Angelica sinensis: Botany, Traditional Uses, Phytochemistry, Pharmacology, Safety, and Applications](https://pubmed.ncbi.nlm.nih.gov/42366516/) - Zhang et al., 2026

  The most current comprehensive narrative review of the root, cataloguing over 290 constituents and mapping structure-activity relationships for Z-ligustilide and ferulic acid alongside a frank account of evidence gaps.

* [Research Progress in Pharmacological Effects and Mechanisms of Angelica sinensis against Cardiovascular and Cerebrovascular Diseases](https://pubmed.ncbi.nlm.nih.gov/38731591/) - Chen et al., 2024

  A mechanism-focused narrative review covering the root's vascular, antiplatelet and anti-inflammatory actions — the pathways most relevant to anyone using it with a longevity rather than gynecological intent.

* [Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial](https://pubmed.ncbi.nlm.nih.gov/9418683/) - Hirata et al., 1997

  The single best-designed trial of the unblended root: 24 weeks, 71 women, and no effect on endometrial thickness, vaginal cell maturation, or hot flashes. Still the reference point for null findings.

* [A randomized, double-blind, placebo-controlled study on the anti-haemostatic effects of Curcuma longa, Angelica sinensis and Panax ginseng](https://pubmed.ncbi.nlm.nih.gov/28732813/) - Fung et al., 2017

  The only controlled human test of the bleeding concern, measuring platelet aggregation, clotting times and thrombin generation with and without aspirin — the key counterweight to the case-report literature.

* [Female Hormone Restoration](https://www.lifeextension.com/protocols/female-reproductive/female-hormone-restoration) - Williams & Sandhaus

  A practitioner-facing protocol that places dong quai within a broader hormone-support framework and cites the combination-product trials, the androgen-deprivation trial, and the animal bone-density data.

No directly relevant content on this root was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io; searches of their platforms and of the open web returned no article, podcast episode, or commentary that discusses *Angelica sinensis* or dong quai by name, which is consistent with the herb sitting outside the compounds those platforms cover.
  
  
## Grokipedia

<!-- Author's note: grokipedia.com was searched directly with the browser tool for "Angelica sinensis"; the search returned 344 results, of which the first is the site's dedicated primary page for the plant at /page/Angelica_sinensis. -->

[Angelica sinensis](https://grokipedia.com/page/Angelica_sinensis)

The site's dedicated page for the species, covering botany, traditional classification, constituent chemistry and the modern clinical record in one continuous entry rather than splitting supplement and plant coverage.
  
  
## Examine

<!-- Author's note: examine.com was searched directly with the browser tool for "dong quai"; the site's search endpoint returned a bot-detection interstitial, so the supplement page itself was retrieved through a proxy retrieval tier and confirmed to exist at /supplements/dong-quai/. -->

[Dong Quai](https://examine.com/supplements/dong-quai/)

Examine's page filed under the dong quai name in fact summarises *Angelica gigas*, the Korean sister species, so its hormone and immune conclusions do not transfer directly to *Angelica sinensis*.
  
  
## ConsumerLab

<!-- Author's note: consumerlab.com was searched directly for "dong quai"; the browser tool hit a Cloudflare challenge, so the search results page was retrieved through a proxy retrieval tier and read in full. -->

ConsumerLab has no dedicated review, monograph, or product test for *Angelica sinensis*. The herb appears only inside broader articles and in a November 2021 recall notice over possible lead and cadmium contamination.
  
  
## Systematic Reviews

Systematic reviews and meta-analyses covering *Angelica sinensis* and the classical formulas built around it, spanning both the claimed benefits (menstrual pain, renal anemia, lung fibrosis) and the principal risk (interaction with blood-thinning drugs); most of the pooled trials were run at Chinese traditional-medicine hospitals and universities whose clinical income depends on these formulas remaining in use, a conflict of interest none of the source papers discloses.

<!-- Author's note: A real-time PubMed search was performed for (Angelica sinensis OR Dong quai OR Danggui) AND (systematic review[pt] OR meta-analysis[pt]), returning 33 records, supplemented by targeted searches for Danggui Buxue and for herb-warfarin interaction reviews. Selection prioritised direct relevance to the root, study size, recency, and coverage of both benefit and risk. -->

* [Herbal medicine (Danggui Shaoyao San) for treating primary dysmenorrhea: A systematic review and meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/26857875/) - Lee et al., 2016

  Pools four randomized trials of the classical Angelica-Paeonia formula against analgesics and placebo; the largest signal the root participates in.

* [Efficacy and safety of Danggui Buxue Decoction in combination with western medicine treatment of anemia for renal anemia: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/28462216/) - Zhao et al., 2017

  Seven trials, 460 patients; the only pooled test of the blood-tonic claim, and the source of the 5:1 herb-ratio finding.

* [Radix Astragali and Radix Angelicae Sinensis in the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis](https://pubmed.ncbi.nlm.nih.gov/32425767/) - Zhang et al., 2020

  Seventeen trials of the two-herb pair as add-on therapy, reporting lung function, walking distance and adverse-event rates.

* [The Effectiveness of Non-Soy Oral Herbal Supplements for Menopausal Symptoms: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/42451042/) - Jing et al., 2026

  Thirty randomized trials of nineteen herbs; places dong quai among the minority that produced no measurable effect.

* [Warfarin and food, herbal or dietary supplement interactions: A systematic review](https://pubmed.ncbi.nlm.nih.gov/32478963/) - Tan & Lee, 2021

  Catalogues 149 reports across 78 herbs and foods, grading each by likelihood of interaction and severity of bleeding outcome.
  
  
## Mechanism of Action

*Angelica sinensis* acts through several chemical families at once rather than a single receptor.

The dominant volatile constituent, Z-ligustilide, relaxes vascular smooth muscle and suppresses NF-κB (a master switch that turns on inflammatory genes) while activating Nrf2 (a switch that turns on the cell's own antioxidant defences). Ferulic acid, the principal plant acid, scavenges free radicals and inhibits thromboxane-driven platelet clumping. The root's polysaccharides act on the bone marrow, promoting red-cell precursor proliferation and lowering hepcidin (the hormone that locks iron inside storage cells), which raises circulating iron. A separate coumarin fraction carries mild anticoagulant structure, and water extracts show weak estrogen-receptor agonism.

Competing mechanistic accounts exist. One school treats the root as a genuine phytoestrogen, pointing to receptor binding and cell proliferation in laboratory models; the opposing account holds that human doses never reach estrogenic concentrations, citing [the trial](https://pubmed.ncbi.nlm.nih.gov/9418683/) in which 24 weeks of the root left endometrial thickness and vaginal cell maturation unchanged.

Key pharmacological properties are set by the markers rather than the whole root. Ferulic acid is absorbed fast (peak at roughly 28 minutes) with an elimination half-life near 2.2 hours and a very large distribution volume, and is cleared by glucuronidation and sulfation with CYP-enzyme (liver drug-metabolising enzyme) involvement. Z-ligustilide is highly fat-soluble, crosses into brain tissue, and is chemically unstable in air and light.
  
  
## Historical Context & Evolution

*Angelica sinensis* entered the written record in the Shennong Bencao Jing around the first century, classified as a warming agent that "nourishes and moves the blood." Its original indications were narrow and concrete: irregular or painful menstruation, recovery after childbirth or blood loss, dry constipation, and cold, poorly perfused limbs. It was almost never given alone. Danggui Buxue Tang, formalised in 1247, fixes it at one part to five parts Astragalus; Danggui Shaoyao San and Danggui Sini Tang embed it in six- and seven-herb combinations.

Its reframing as a health-optimisation agent came from two directions. Laboratory work in the 1980s and 1990s identified ligustilide, ferulic acid and the polysaccharide fraction, giving the "blood-moving" language a vascular and hematopoietic reading that Western readers could act on. Simultaneously, the herb was marketed abroad as a hormone-free alternative for menopausal symptoms.

That reframing has been repeatedly tested. [The 1997 placebo-controlled trial](https://pubmed.ncbi.nlm.nih.gov/9418683/) found no estrogenic change and no symptom relief from the root alone; combination products containing it have reported large reductions in flushing. Rather than settling the question, the split relocated it — whether the root is inert, or active only in company.

Structural incentives shape which reading gets funded. In China, traditional formulas are reimbursed by the state insurance system and produced by listed pharmaceutical firms, so trial funding flows toward positive formula-level results; in Western systems the root is an unreimbursed self-paid supplement competing against reimbursed hormone therapy, and neither payer has reason to fund head-to-head comparisons.
  
  
## Expected Benefits

<!-- Author's note: A dedicated search of the complete benefit profile was performed before this section was written, combining PubMed searches for Angelica sinensis trials, meta-analyses and formula-level studies, clinicaltrials.gov registry queries, and expert-source review, to ensure no established or claimed benefit domain was omitted. -->

### High 🟩 🟩 🟩

#### Reduced Menstrual Pain in Primary Dysmenorrhoea

Angelica-based formulas outperform analgesics for period pain. Two independent meta-analyses cover this: four randomized trials of [Danggui Shaoyao San](https://pubmed.ncbi.nlm.nih.gov/26857875/) and eleven trials with 1,005 patients of [Danggui Sini Decoction](https://pubmed.ncbi.nlm.nih.gov/33228406/), both favouring the herbal arm on response rate. The mechanism is presumed to combine smooth-muscle relaxation with prostaglandin-pathway suppression. The critical limitation is that the root is never tested alone here, and nearly all pooled trials carry high risk of bias from unblinded design and short follow-up.

**Magnitude:** Response rate roughly 31% higher than analgesics (risk ratio 1.31, 95% confidence interval 1.06–1.63), with substantial disagreement between the pooled trials (I² = 73%, a measure of that inconsistency).

### Medium 🟩 🟩

#### Improved Red-Cell Indices in Anemia of Chronic Kidney Disease

Added to conventional anemia treatment, the classical Angelica-Astragalus pairing improves red-cell measures in kidney patients. A [meta-analysis of seven randomized trials in 460 patients](https://pubmed.ncbi.nlm.nih.gov/28462216/) found gains in red-cell count and hematocrit (the percentage of blood volume made of red cells), with hemoglobin improving only when the classical five-to-one herb ratio was used. The proposed mechanism is polysaccharide-driven marrow stimulation plus hepcidin suppression. Trial quality was rated poor throughout and safety reporting was thin.

**Magnitude:** Red-cell count about 0.49 × 10¹²/L higher and hematocrit about 1.9 percentage points higher than standard care alone; hemoglobin about 16 g/L higher only at the five-to-one ratio.

#### Relief of Menopausal Vasomotor Symptoms ⚠️ Conflicted

Evidence here points in opposite directions depending on whether the root is given alone or blended. The root alone failed in a [24-week placebo-controlled trial](https://pubmed.ncbi.nlm.nih.gov/9418683/) and in [men on androgen-deprivation therapy](https://pubmed.ncbi.nlm.nih.gov/20165579/); the Angelica-Astragalus decoction beat placebo only for mild flushes in [one trial](https://pubmed.ncbi.nlm.nih.gov/18568789/) but reduced flush frequency dose-dependently in [another](https://pubmed.ncbi.nlm.nih.gov/22990757/). A [chamomile combination](https://pubmed.ncbi.nlm.nih.gov/14664413/) produced the largest effect recorded. The most plausible reconciliation is that partner herbs, not the root, carry the effect.

**Magnitude:** Single-herb trials show no separation from placebo; the chamomile combination cut hot flushes 90–96% versus 15–25% on placebo, and 6 g/day of the decoction reduced flush frequency and severity by roughly 35–37%.

#### Improved Exercise Tolerance in Idiopathic Pulmonary Fibrosis

As an add-on to standard care for scarring of the lungs, the Angelica-Astragalus pair improved lung function tests, six-minute walking distance and breathlessness scores across a [meta-analysis of 17 randomized trials](https://pubmed.ncbi.nlm.nih.gov/32425767/), and the herbal arm reported fewer adverse reactions than control. Proposed mechanisms centre on ligustilide's suppression of fibrotic signalling. All included trials were conducted in China with unblinded designs and composite "total effective rate" endpoints, which inflate apparent benefit.

**Magnitude:** Direction is consistently favourable across all 17 trials for lung function, walking distance and breathlessness, holding for add-on rather than replacement use; the pooled report gives significance levels but no single outcome figure.

### Low 🟩

#### Reduced Proteinuria in Early Chronic Kidney Disease

A [24-week multicentre trial in 158 patients with glomerulonephritis](https://pubmed.ncbi.nlm.nih.gov/27468543/) (inflammation of the kidney's filters) compared an Astragalus-Angelica particle against losartan 50 mg/day. Protein leakage into urine fell continuously in the herbal arm while the losartan arm plateaued after week 12. Filtration rate and blood pressure stayed stable. Single-country and open-label.

**Magnitude:** Greater reduction in 24-hour urinary protein than losartan from week 16 through week 24 (P < 0.001); the report gives significance levels but no absolute gram-per-day difference.

#### Improved Cognitive Scores in Dementia

A [meta-analysis of nine trials in 567 participants](https://pubmed.ncbi.nlm.nih.gov/31977846/) found Danggui Shaoyao San improved cognitive screening scores and daily-living scores in Alzheimer's and vascular dementia. Trials were small and mostly low quality, and the formula's other constituents may drive the effect.

**Magnitude:** Cognitive screening score about 4.6 points higher than control in Alzheimer's disease (95% confidence interval 4.29–4.91) and daily-living score about 11.4 points higher.

#### Blunted Exercise-Induced Iron Sequestration

In [36 recreational male runners](https://pubmed.ncbi.nlm.nih.gov/30231484/), 11 days of the Angelica-Astragalus decoction suppressed the hepcidin rise that normally follows hard endurance work, raising circulating iron and shortening a 13 km time trial. Single small trial, no anti-inflammatory or hemolysis effect, and no replication.

**Magnitude:** Finish time 14.0% shorter (12.3 minutes) than placebo; serum iron 63.3% higher immediately post-exercise and 31.4% higher at 72 hours.

#### Preserved White-Cell Counts During Cancer Therapy

In [58 breast cancer patients on chemotherapy or radiotherapy](https://pubmed.ncbi.nlm.nih.gov/21864416/), a four-herb complex containing *Angelica sinensis* limited the fall in white cells and neutrophils over six weeks. Effects on T cells and natural-killer cells were not significant, and the root's individual contribution is unresolved.

**Magnitude:** Leucocyte decline 13.4% versus 31.5% on placebo; neutrophil decline 11.0% versus 35.6%.

### Speculative 🟨

#### Neurovascular Protection After Ischemic Stroke

Root extracts and isolated Z-ligustilide and ferulic acid reduce infarct size and promote vessel and neuron regrowth in animal stroke models, per a [systematic review](https://pubmed.ncbi.nlm.nih.gov/34362631/). The basis is entirely preclinical; no human stroke trial exists.

#### Slowing of Age-Related Tissue Fibrosis

Ligustilide and the polysaccharide fraction suppress fibrotic signalling in liver, lung and kidney animal models, as catalogued in a [pharmacology review](https://pubmed.ncbi.nlm.nih.gov/42366516/). Mechanistic and animal data only; no human study has measured tissue fibrosis.
  
  
## Benefit-Modifying Factors

* **Baseline hemoglobin and iron stores:** The blood-tonic benefits appear only where there is a deficit to correct. Trials showing red-cell and iron gains recruited anemic kidney patients or endurance athletes with depleted iron; iron-replete users have no measured room to improve.

* **Estrogen-receptor status and menopausal stage:** Weak receptor agonism means the herb behaves differently against a high versus low estrogen background. Perimenopausal women with fluctuating estradiol showed less consistent flush relief than the fully postmenopausal cohorts in the combination-product trials.

* **Sex-based differences:** Every positive vasomotor trial recruited women. The one trial in men, on androgen-deprivation therapy for prostate cancer, found no effect on hot flash frequency, severity or duration, suggesting the benefit is not simply a general thermoregulatory action.

* **Kidney function:** Both the anemia and the proteinuria findings come from patients with established kidney disease at stage 2 or worse. Benefit magnitude scaled with baseline impairment; users with normal filtration rates have no comparable evidence base.

* **Age at the older end of the range:** Adults over 65 carry a higher prevalence of anticoagulant use, polypharmacy and reduced kidney clearance, which shifts the risk-benefit balance rather than the benefit itself. Cognitive-score trials, by contrast, recruited exclusively in this age band.

* **CYP2C9 and VKORC1 variants:** These affect how fast warfarin is broken down (CYP2C9, a liver enzyme) and how sensitive its target is (VKORC1, the vitamin K recycling enzyme). Carriers of slow-metabolising variants have less margin before any added anticoagulant effect becomes clinically visible.

* **Preparation and herb ratio:** Benefit tracked the formula, not the root. The [renal anemia meta-analysis](https://pubmed.ncbi.nlm.nih.gov/28462216/) found hemoglobin gains only at the classical five-to-one Astragalus-to-Angelica ratio, and none at other ratios — a reminder that "dong quai" products are not interchangeable.
  
  
## Potential Risks & Side Effects

<!-- Author's note: A dedicated search of the complete side-effect profile was performed before this section was written, drawing on drug-reference and regulatory sources (drugs.com monograph, LiverTox, the EFSA FEEDAP opinion on dong quai tincture, the ConsumerLab recall record) alongside PubMed searches for case reports, interaction studies and toxicology. -->

### High 🟥 🟥 🟥

#### Potentiation of Warfarin and Other Anticoagulants ⚠️ Conflicted

The root carries coumarin-type constituents structurally related to anticoagulant drugs. A [systematic review of 149 interaction reports](https://pubmed.ncbi.nlm.nih.gov/32478963/) places dong quai among herbs credibly reported to potentiate warfarin, and a [published case](https://pubmed.ncbi.nlm.nih.gov/10417036/) documented a more than two-fold rise in clotting time in a stabilised patient, reversing a month after stopping. Against this, a [randomized placebo-controlled trial in healthy volunteers](https://pubmed.ncbi.nlm.nih.gov/28732813/) found no effect on platelet aggregation, clotting times or thrombin generation, alone or with aspirin.

**Magnitude:** Prothrombin time and international normalised ratio (a standardised measure of how long blood takes to clot) more than doubled in the reported case; in healthy volunteers 2 of 24 showed isolated platelet-aggregation inhibition and no measurable change in clotting times.

### Medium 🟥 🟥

#### Growth Stimulation of Estrogen-Receptor-Positive Breast Cancer Cells

Water extracts of the root dose-dependently stimulated proliferation of hormone-receptor-positive breast cancer cells in [laboratory culture](https://pubmed.ncbi.nlm.nih.gov/16278617/), an effect reversible by tamoxifen, and also drove growth of receptor-negative cells through a separate route. In [mice carrying human tumour grafts](https://pubmed.ncbi.nlm.nih.gov/34271113/) the extract induced tumour growth and cancer-stem-cell activity via receptor induction. No human outcome study exists, so the transfer from model to person is unproven — but the signal is concordant across cell and animal systems.

**Magnitude:** Tumour growth induced at 2.5 mg/kg in the xenograft model with receptor upregulation; cell proliferation rose dose-dependently in culture. No human incidence figure exists because no cohort or trial has tracked this outcome.

#### Gastrointestinal Upset and Laxative Effect

The root is traditionally used to moisten the bowel, and loose stools, bloating and abdominal discomfort are the adverse events most often recorded in its clinical studies, as summarised in a [comprehensive safety and pharmacology review](https://pubmed.ncbi.nlm.nih.gov/42366516/). Effects are dose-related and resolve on stopping. In the [dose-escalation trial](https://pubmed.ncbi.nlm.nih.gov/22990757/) that ran to 6 g/day for 12 weeks, tolerability remained acceptable with no serious adverse events, which bounds the severity.

**Magnitude:** Symptoms are dose-related, appearing chiefly above roughly 3–6 g/day of dried root equivalent and resolving on withdrawal; the trial literature reports tolerability narratively and gives no incidence figure.

### Low 🟥

#### Gynecomastia and Hormone-Like Effects in Men

A [case report](https://pubmed.ncbi.nlm.nih.gov/11405562/) describes breast tissue enlargement in a man taking concentrated dong quai tablets, attributed to phytoestrogen content that concentrated oral preparations can carry well above whole-root levels. It resolved on discontinuation. A single case, but consistent with the receptor-agonism data.

**Magnitude:** One reported case; the literature gives no incidence figure because no cohort study has measured hormone-sensitive endpoints in male users.

#### Photosensitivity from Furanocoumarins

*Angelica* species accumulate psoralen-type furanocoumarins, catalogued for the genus in a [chemistry review](https://pubmed.ncbi.nlm.nih.gov/40802895/); this compound class is [established as phototoxic and photogenotoxic](https://pubmed.ncbi.nlm.nih.gov/24680798/), reacting with skin DNA under ultraviolet light. Root content is far below therapeutic psoralen doses.

**Magnitude:** Phototoxic potency scales with total furanocoumarin content, which in *Angelica sinensis* root sits well below the levels used in medical psoralen therapy; no clinical study reports a burn incidence for the root.

#### Skin and Respiratory Sensitisation

The [European Food Safety Authority assessment](https://pubmed.ncbi.nlm.nih.gov/36540776/) classified dong quai tincture as irritant to skin and eyes and a dermal and respiratory sensitiser — a handling, not ingestion, risk. The dossier came from FEFANA, a feed-additive trade association, yet the publicly funded panel imposed limits against that sponsor's interest.

**Magnitude:** Classification is hazard-based rather than dose-based; the assessment sets safe feed concentrations of 79–481 mg/kg by species but reports no human sensitisation rate.

#### Heavy-Metal and Adulterant Exposure

A [molecular audit of 26 traditional Chinese medicine products](https://pubmed.ncbi.nlm.nih.gov/26658160/) found 92% carried contamination or substitution, including arsenic, lead, cadmium and undeclared drugs. A 2021 US recall pulled an Angelicae Sinensis product over lead and cadmium. A supply-chain risk, not a plant property.

**Magnitude:** 92% of audited products showed contamination or substitution, with one arsenic level more than ten times the acceptable limit.

### Speculative 🟨

#### Carcinogenic Potential of Safrole-Type Constituents

Early pharmacology writing on the root, including [a clinical case report](https://pubmed.ncbi.nlm.nih.gov/10417036/), listed carcinogenic constituents alongside antithrombotic and phototoxic ones. The basis is compound-class inference, not human data; no epidemiological signal has been reported.

#### Uterine Stimulation and Pregnancy Risk

Traditional practice contraindicates the root in early pregnancy, and animal work shows uterus-contracting activity, as noted in the [current pharmacology review](https://pubmed.ncbi.nlm.nih.gov/42366516/). No human pregnancy data exist; the basis is mechanistic and traditional.
  
  
## Risk-Modifying Factors

* **CYP2C9 and VKORC1 genotype:** Poor-metaboliser CYP2C9 variants and sensitive VKORC1 variants leave a narrower safety margin on warfarin, so any added anticoagulant effect from the root shows up sooner and larger in these carriers.

* **Baseline clotting measures:** An international normalised ratio already at the top of its target range, low platelets, or existing antiplatelet use compresses the buffer against the interaction. Users with normal counts have essentially no measured bleeding risk.

* **Sex-based differences:** Men face the hormone-like risks disproportionately, with the only gynecomastia case occurring in a male user; women face the estrogen-sensitive tissue risk, which has no male equivalent given the tumour models used.

* **Hormone-sensitive disease history:** Personal or family history of estrogen-receptor-positive breast cancer, endometrial hyperplasia or uterine fibroids converts the receptor-agonism finding from theoretical to decision-relevant, since these tissues respond to the same signal.

* **Age at the older end of the range:** Adults over 65 use anticoagulants more often, clear coumarins more slowly, and bleed more consequentially. Falls risk compounds this. The heavy-metal exposure risk also accumulates over longer use histories.

* **Kidney and liver impairment:** Reduced clearance prolongs exposure to coumarin and phthalide constituents, and impaired kidneys reduce excretion of any heavy-metal contaminants the product carries, raising retention in bone and soft tissue.

* **Fair skin and high ultraviolet exposure:** The palest, most easily burned skin types combined with intense sun or tanning-bed use raise the theoretical furanocoumarin phototoxicity concern from negligible toward relevant, particularly with concentrated extracts.
  
  
## Key Interactions & Contraindications

* **Warfarin (absolute caution, monitor closely):** Coumarin constituents may add to vitamin K antagonism, risking clotting time elevation and bleeding. The mitigating action is international normalised ratio testing at 1 and 2 weeks after any change, with the herb held if it drifts above target.

* **Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) (caution):** No interaction data exist, but these drugs lack a routine monitoring test, so an added effect would be invisible until bleeding occurs. The combination therefore carries unmonitored risk.

* **Antiplatelet drugs (clopidogrel, ticagrelor, prasugrel) (caution):** Ferulic acid inhibits thromboxane-driven platelet clumping, plausibly additive. Consequence is bruising and prolonged bleeding; the mitigating action is a two-week washout before elective procedures.

* **Aspirin and NSAIDs (non-steroidal anti-inflammatory painkillers such as ibuprofen and naproxen) (monitor):** A trial found no added platelet inhibition when the root was combined with aspirin, but these drugs independently erode stomach lining, making gastrointestinal bleeding the signal that matters.

* **Tamoxifen and aromatase inhibitors (letrozole, anastrozole — drugs that shut down the body's own estrogen production) (absolute contraindication):** Root extract stimulates receptor-positive tumour growth in animal models; tamoxifen suppressed that growth, implying direct opposition at the same receptor.

* **Estrogen therapy and hormonal contraceptives (caution):** Weak receptor agonism may add to exogenous estrogen exposure in breast and endometrial tissue. Consequence is theoretical proliferation risk; concurrent use belongs under gynecological review of total estrogenic load.

* **Photosensitising drugs (doxycycline, amiodarone, voriconazole, retinoids) (caution):** Furanocoumarins add to drug-induced ultraviolet sensitivity, risking exaggerated sunburn. The mitigating action is high-factor sunscreen and avoidance of tanning beds rather than dose change.

* **Other blood-moving supplements (ginkgo, high-dose fish oil, garlic extract, vitamin E, nattokinase, curcumin) (monitor):** These share antiplatelet or anticoagulant action, so combining stacks the same risk. Consequence is additive bleeding tendency, mitigated by keeping to one such agent.

* **Iron supplements (potentiating, generally desirable):** Hepcidin suppression raises iron availability, so concurrent iron may push ferritin higher than intended. Consequence is iron overload in carriers of hereditary hemochromatosis, with ferritin rechecked at 12 weeks.

* **Sedatives and alcohol (monitor):** Many commercial dong quai products are alcohol tinctures, adding an ethanol load that compounds sedative effects. Capsules and decoctions carry no such load.

**Populations who should avoid Angelica sinensis:**

* Anyone with current or prior estrogen-receptor-positive breast cancer, or on tamoxifen or an aromatase inhibitor
* Anyone with endometrial hyperplasia or unexplained vaginal bleeding
* Pregnancy at any stage, and particularly the first trimester, on uterotonic grounds
* Breastfeeding, on absent-safety-data grounds
* Anyone on warfarin whose international normalised ratio is unstable or above target range
* Anyone with an inherited bleeding disorder, platelet count below 100 × 10⁹/L, or active peptic ulcer
* The two weeks before and after any surgery, dental extraction, or neuraxial procedure
* Anyone with hereditary hemochromatosis or transferrin saturation above 45%
  
  
## Risk Mitigation Strategies

* **Baseline and repeat clotting checks:** For anyone on warfarin, measuring international normalised ratio before starting and at 1, 2 and 4 weeks, then quarterly, catches the anticoagulant potentiation documented in case reports before bleeding occurs.

* **Two-week perioperative washout:** Stopping at least 14 days before any scheduled surgery, dental extraction, colonoscopy with biopsy, or epidural, and resuming only after a surgeon clears hemostasis, prevents intraoperative and post-procedural bleeding.

* **Low starting dose with slow escalation:** Beginning at 1.5 g/day of dried root equivalent and holding two weeks before stepping to 3 g/day and, if needed, 6 g/day limits the dose-related loose stools and abdominal discomfort.

* **Third-party tested products only:** A current certificate of analysis showing heavy-metal limits met and species identity confirmed directly addresses the lead, cadmium and arsenic contamination found in 92% of audited traditional products.

* **Hormone-sensitive screening before starting:** Confirming the absence of personal or family history of receptor-positive breast cancer, endometrial hyperplasia or unexplained bleeding screens out the population for whom the animal tumour-growth finding is decision-relevant.

* **Ferritin ceiling for iron-focused use:** Where the herb supports iron status, rechecking ferritin and transferrin saturation at 12 weeks and stopping above 200 ng/mL or 45% saturation prevents iron overload from hepcidin suppression.

* **Sun-exposure precautions with concentrated extracts:** High-factor sunscreen and avoidance of tanning beds while concentrated extracts are taken, particularly alongside photosensitising drugs, mitigates the furanocoumarin phototoxicity risk.

* **Single blood-moving agent at a time:** Not stacking with ginkgo, high-dose fish oil, garlic extract or nattokinase prevents the additive antiplatelet effect that turns individually negligible risks into a measurable bleeding tendency.
  
  
## Therapeutic Protocol

* **Standard traditional protocol:** Decocted dried root at 3–15 g/day, almost always within a formula rather than alone, taken as a warm water decoction split across two doses and continued for cycles of 4–12 weeks.

* **Trial-derived supplement protocol:** The dose-escalation trial identified 6 g/day of Danggui Buxue Tang granules over 12 weeks as the effective dose for vasomotor symptoms, with 1.5 and 3 g/day producing weaker responses.

* **Competing approach — formula-based practice:** Chinese and Korean clinical practice, formalised by Li Dongyuan's 1247 Danggui Buxue Tang, holds that the root requires a partner herb; Astragalus at five parts to one is the reference pairing.

* **Competing approach — single-herb Western supplementation:** Western supplement practice sells standardised single-root capsules at 500–2,000 mg/day, typically standardised to ligustilide or ferulic acid content, on the premise that the root is independently active.

* **Best time of day:** Traditional practice gives decoctions warm on an empty stomach, morning and early evening. Users reporting loose stools generally do better taking it with food, and evening dosing avoids the daytime warmth some report.

* **Half-life and dosing frequency:** Ferulic acid's half-life is roughly 2.2 hours and ligustilide's is shorter still, so single daily dosing leaves most of the day unexposed; split dosing twice or three times daily matches the pharmacokinetics.

* **Single versus split dosing:** Every positive controlled trial used split dosing — twice daily granules or a decoction divided across the day. No trial has tested once-daily administration, so split dosing is the only protocol with supporting data.

* **Genetic polymorphisms influencing protocol:** CYP2C9 and VKORC1 variants govern warfarin sensitivity, which shifts anyone on that drug toward avoidance rather than dose adjustment. No pharmacogenetic marker predicts response to the root itself.

* **Sex-based differences in response:** All positive vasomotor and menstrual trials recruited women; the single trial in men found nothing. Men using it for blood-building or vascular reasons are extrapolating beyond the trial population.

* **Age-related considerations:** Traditional dosing does not adjust for age, though the low end of the range fits adults over 65 given slower clearance, higher anticoagulant use, and greater bleeding consequence from any interaction.

* **Baseline biomarkers influencing response:** Hemoglobin, ferritin and transferrin saturation predict whether the blood-building effects have room to appear. Kidney filtration rate identifies the population in which the anemia and proteinuria findings were generated.

* **Pre-existing conditions influencing response:** Chronic kidney disease, iron-deficiency anemia and primary dysmenorrhoea define the populations where controlled trials found effects. Healthy iron-replete users have no trial evidence predicting any measurable response.
  
  
## Discontinuation & Cycling

* **Not a lifelong intervention:** Every controlled trial ran 6 to 24 weeks. No study has followed continuous use beyond six months, so open-ended daily use sits entirely outside the evidence base.

* **Traditional cycling pattern:** Classical practice gives the root in courses tied to a condition or menstrual cycle rather than continuously, typically 4–12 weeks, then reassessment. This pattern is convention, not trial-derived.

* **No withdrawal syndrome documented:** No trial or case report describes withdrawal effects, rebound symptoms, or dependence on stopping. Symptoms that the herb was suppressing simply return at their prior level.

* **No taper required:** Because no withdrawal effects exist, abrupt discontinuation is acceptable and is what perioperative guidance requires. The only reason to taper is to distinguish herb effect from natural symptom fluctuation.

* **Cycling for efficacy is unstudied:** No trial has compared continuous against cycled administration, so claims that cycling preserves responsiveness are unsupported. Tolerance to the root's effects has not been demonstrated or excluded.

* **Interaction reversal on stopping:** The documented warfarin potentiation resolved about one month after the herb was withdrawn, so clotting measures warrant a recheck several weeks after stopping, not only after starting.
  
  
## Sourcing and Quality

* **Species identity is the first check:** Products labelled "dong quai" may contain *Angelica gigas* or *Angelica acutiloba* rather than *Angelica sinensis*. The binomial on the label and a certificate of analysis confirming botanical identity separate them.

* **Part of plant matters:** Only the root carries the traditional and trial evidence. Aerial parts and leaf preparations have a different constituent profile and are used mainly in animal feed, not human supplementation.

* **Heavy-metal testing is non-negotiable:** The 2021 lead and cadmium recall and the broader contamination audit make a current heavy-metal certificate the single most important quality signal for this herb.

* **Third-party certification:** United States Pharmacopeia, NSF International or Informed Choice verification, or an independent laboratory certificate covering identity, heavy metals, pesticides and microbial limits, carries weight; self-declared "purity" claims carry none.

* **Standardisation markers:** Better products state ferulic acid or ligustilide content. Ligustilide degrades with heat, light and air, so a stated content plus opaque packaging and a recent manufacture date indicate real handling control.

* **Geographic origin:** Gansu province, particularly Min County, supplies most pharmacopoeial-grade root. Origin statements matter because soil cadmium varies regionally and drives the contamination risk more than processing does.

* **Form selection:** Granulated decoction extracts match the trial products most closely; alcohol tinctures add an ethanol load; raw sliced root requires home decoction. Capsule products vary widely in extract ratio, which labels often omit.
  
  
## Practical Considerations

* **Time to effect:** Menstrual pain trials measured across one to three cycles; anemia and kidney trials needed 12 to 24 weeks. Nothing in the literature supports judging the herb before at least eight weeks of consistent use.

* **Common pitfall — expecting the single root to act:** The strongest findings come from multi-herb formulas. Buying a single-root capsule and expecting the dysmenorrhoea or anemia results is the most frequent mismatch between evidence and purchase.

* **Common pitfall — ignoring the anticoagulant question:** Users on warfarin, antiplatelet drugs or heavy fish oil frequently add the root without rechecking clotting, which is the one interaction with documented human consequence.

* **Common pitfall — dose too low:** Western capsules commonly supply 500 mg, an order of magnitude below the 3–15 g of dried root used traditionally and the 6 g/day of granules used in the positive trial.

* **Regulatory status:** In the United States it is a dietary supplement under DSHEA (the 1994 law that exempts supplements from pre-market approval), so no agency verifies content before sale. It is a registered traditional medicine in China and Taiwan.

* **Cost and accessibility:** Neither expensive nor hard to obtain — bulk root and granules run roughly $15–40 per month. Third-party tested products cost more but remain inexpensive relative to most longevity interventions.
  
  
## Interaction with Foundational Habits

* **Sleep:** Indirect and modest. No trial measured sleep as a primary endpoint, but the combination-product trials reported reduced night sweats and less sleep disturbance, which would improve sleep continuity secondarily. The root has no known sedative or stimulant action; evening dosing is neutral for most users.

* **Nutrition:** Direct and potentiating with iron. Hepcidin suppression raises iron absorption and availability, so pairing with iron-rich meals or supplements amplifies the effect and warrants ferritin monitoring. Taking the decoction with food blunts the laxative effect. No nutrient depletion has been documented.

* **Exercise:** Direct and potentiating for endurance work. In recreational runners, 11 days of the Angelica-Astragalus decoction shortened a 13 km time trial and preserved iron status after hard efforts. No blunting of hypertrophy signalling has been reported. Dosing timing relative to training was not tested.

* **Stress management:** Indirect and weak. The root has no measured effect on cortisol or the stress axis in human studies. Its documented anti-inflammatory signalling is a tissue-level action, not a stress-response one, so it neither substitutes for nor interferes with stress-management practice.
  
  
## Monitoring Protocol & Defining Success

Before starting, the useful baseline set is narrow, targeted at what this herb plausibly moves and what it plausibly endangers. A complete blood count with hemoglobin and hematocrit establishes whether an anemia deficit exists to correct; ferritin and transferrin saturation establish iron status and screen for overload; a kidney panel with estimated filtration rate and urine albumin-to-creatinine ratio applies where kidney disease is the reason for use. Warfarin users need a documented international normalised ratio, antiplatelet users a platelet count.

Ongoing monitoring follows the interaction risk rather than the benefit. For warfarin users, clotting is rechecked at 1, 2 and 4 weeks after starting, then quarterly, and again after stopping. For everyone else, the blood count, iron panel and, where relevant, kidney markers are rechecked at 12 weeks, then every 6 months.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Hemoglobin | 13.5–15.0 g/dL (women), 14.5–16.5 g/dL (men) | Tracks whether the blood-tonic effect is producing anything measurable | Conventional labs flag only below 12.0 (women) or 13.5 (men); the functional target sits higher. Non-fasting |
| Hematocrit | 38–44% (women), 42–48% (men) | The endpoint that improved most consistently in the renal anemia meta-analysis | Rises with dehydration, so it is drawn at consistent hydration and paired with hemoglobin and red-cell count |
| Ferritin | 50–150 ng/mL | Iron store status; identifies both a deficit to correct and an overload ceiling | Rises with inflammation, so it is paired with hs-CRP (high-sensitivity C-reactive protein, an inflammation marker). Above 200 ng/mL is the stop threshold |
| Transferrin saturation | 25–40% | Detects iron overload risk from hepcidin suppression, especially in hemochromatosis carriers | Fasting morning draw; afternoon values run higher. Above 45% is the stop threshold |
| International normalised ratio | Within the individual's prescribed warfarin target, usually 2.0–3.0 | The only marker with a documented human interaction consequence | Applies only to warfarin users. Checked at 1, 2 and 4 weeks after any change, then quarterly, and after stopping |
| Estimated glomerular filtration rate | Above 90 mL/min/1.73 m², or stable against the individual's own baseline | Tracks the kidney population in which the proteinuria finding was generated | Fasting not required. Interpreted alongside the urine albumin ratio rather than alone |
| Urine albumin-to-creatinine ratio | Below 30 mg/g, or falling from the individual's own baseline | The endpoint that outperformed losartan in the glomerulonephritis trial | First-morning void; exercise within 24 hours falsely raises it |

Qualitative markers matter as much as the labs, because most of what users chase has no biomarker:

* Menstrual pain intensity and analgesic tablets used per cycle, tracked across at least three cycles
* Hot flush and night sweat frequency and severity, logged daily rather than recalled
* Energy and exertional fatigue during habitual training, compared against a pre-start reference week
* Stool frequency and consistency, as the earliest signal that the dose is too high
* Bruising, gum bleeding, or unusually long bleeding from minor cuts, as the earliest signal of the anticoagulant interaction
* Cold hands and feet, the traditional indication and the symptom users most often report changing first
  
  
## Emerging Research

* **Dysmenorrhoea formula trial:** [NCT06730282](https://clinicaltrials.gov/study/NCT06730282) at Taichung Tzu Chi Hospital randomizes 200 participants to Danggui Shaoyao San, *Cuscuta chinensis*, both, or placebo for primary dysmenorrhoea, with pain on a visual analogue scale as the primary endpoint — the first registered trial to isolate formula components against period pain.

* **Herbal anemia adjunct:** [NCT04974073](https://clinicaltrials.gov/study/NCT04974073), a completed phase 3 study of 39 participants at China Medical University Hospital, tested the Angelica-Astragalus decoction (PHY606) at 7.5 g twice daily for three months, with serum cytokines and a constitutional questionnaire as endpoints. Results remain unpublished.

* **Kidney function protection:** [NCT05387187](https://clinicaltrials.gov/study/NCT05387187), a phase 2/3 study of 40 chronic kidney disease patients at Taipei Medical University Hospital, adds Pu Yang Wan Wu Tang, which contains *Angelica sinensis*, to pentoxifylline, with filtration rate as the endpoint. Underpowered, but directly relevant to the proteinuria signal.

* **Reproductive-endocrine use:** [NCT05875233](https://clinicaltrials.gov/study/NCT05875233), a 70-participant study of a commercial Angelica-containing blend in polycystic ovary syndrome, tracks cycle regularity and androgen-driven acne. Sponsored by the product manufacturer, which is a direct conflict of interest, and its status is currently unknown.

* **Isolating the root from its formula:** The most consequential open question is whether *Angelica sinensis* does anything alone. The null single-herb result of [Hirata et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9418683/) and the positive combination result of [Kupfersztain et al., 2003](https://pubmed.ncbi.nlm.nih.gov/14664413/) remain unreconciled by any three-arm design comparing root, partner herb, and the pair.

* **Evidence that could weaken the case:** The xenograft tumour-growth finding of [Zhu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34271113/) has not been followed by any human cohort study of hormone-sensitive cancer incidence in long-term users. A registry analysis showing elevated incidence would remove the herb from consideration for many current users.

* **Evidence that could strengthen the case:** The hepcidin suppression finding of [Chang et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30231484/) in runners has an obvious longevity extension — iron dysregulation in older adults — and replication with hard iron endpoints in an older cohort would give the root a use case independent of gynecology.
  
  
## Conclusion

*Angelica sinensis* is an old and heavily traded Chinese root whose modern evidence base is real but narrow, and whose most reliable findings belong to the formulas it sits in rather than to the root itself. Where multi-herb preparations built around it have been tested, they reduce menstrual pain more than painkillers, improve red-cell measures in kidney-related anemia, and improve breathing tolerance in lung scarring. Where the root has been tested alone in careful placebo-controlled conditions, it has repeatedly done nothing — including for the menopausal flushing that sells most of it in the West.

The safety picture is dominated by one documented human interaction and one unresolved laboratory signal. Reports of exaggerated blood thinning alongside warfarin conflict with a controlled trial that found no clotting effect, so the interaction stands as neither established nor excluded. Separately, the root promotes growth of hormone-receptor-positive tumour cells in animal models, with no human data either way.

The evidence carries the mark of its origins. Most positive trials come from institutions and companies whose income depends on these formulas, quality across the pooled trials was consistently rated poor, and marketed products vary enough in species, dose and contamination that two bottles labelled the same herb may share little.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**